Community
Company
News
Contact Us
Sign in

Please select the option that best describes you:

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic

Would you offer adjuvant endocrine therapy to a male with ER+ DCIS?

Related Questions

Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/HER2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?

Is there evidence supporting the use of nab-paclitaxel in place of paclitaxel in the KEYNOTE-522 neoadjuvant regimen for triple-negative breast cancer, in cases of paclitaxel hypersensitivity?

Would you recommend adjuvant chemotherapy for older patients >75 years of age with T4b grade 2 HR+, HER2- mucinous carcinoma of the breast?

Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?

In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2-negative breast cancer, what is the preferred adjuvant chemotherapy regimen for premenopausal women — AC-T or TC?

Would you add pertuzumab to adjuvant therapy for a premenopausal female with HR+, HER2+ IDC with N1mic disease?

How do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies for patients with germline BRCA1/2 mutations?

Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?

What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?

When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?

Copyright © 2025 theMednet
All Rights Reserved.